-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Sodium Glycero-phosphate Injection (10 ml: 2.16 g) by Shijiazhuang Sihua Pharmaceutical Group Has Been Approved
Category:
发布时间：2025-12-25
【概要描述】
At the year’s end, good news abounds as we sprint toward the completion of our annual R&D objectives and achieve yet another significant milestone! On December 25, Shijiazhuang Sihua Pharmaceutical Group received approval from the National Medical Products Administration for the production registration of its Class 4 chemical drug—sodium glycerophosphate injection (10 mL: 2.16 g)—which is also deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs, making it the third such product approved in China. This marks the Group’s 93rd newly approved product this year and its 69th new dosage-form product.
At the year’s end, good news abounds as we sprint toward our annual R&D targets and achieve yet another significant milestone! On December 25, Shijiazhuang Sihua Pharmaceutical Group’s Class 4 chemical drug—sodium glycerophosphate injection (10 mL: 2.16 g)—received production registration approval from the National Medical Products Administration, and is deemed to have passed the evaluation of generic drug quality and therapeutic equivalence, making it the third such product approved in China. This marks the group’s 93rd new product approval this year and its 69th new dosage-form product approval.
According to available information, sodium glycerophosphate injection is a nutritional drug that can be used as a phosphorus supplement in parenteral nutrition for adults and in patients with phosphorus deficiency. Data from MeneNet indicate that in 2024, sales of sodium glycerophosphate injection across China’s three major distribution channels—urban public hospitals, county-level public hospitals, and township health centers—totaled approximately RMB 50 million, with first-half 2025 sales reaching about RMB 30 million.
The approval of sodium glycerophosphate injection this time further enriches the Group’s product portfolio in the areas of electrolyte and acid–base balance, as well as mineral and nutritional supplementation. To date, the Group has a total of 166 drug varieties comprising 217 dosage forms that have either passed or are deemed to have passed the bioequivalence and therapeutic equivalence evaluation for generic drugs.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091